Literature DB >> 22336080

Inhibition of angiogenesis by IL-32: possible role in asthma.

Norbert Meyer1, Janine Christoph, Heidi Makrinioti, Philippe Indermitte, Claudio Rhyner, Michael Soyka, Thomas Eiwegger, Maciej Chalubinski, Kerstin Wanke, Hiroyuki Fujita, Paulina Wawrzyniak, Simone Bürgler, Sherrie Zhang, Mübeccel Akdis, Günter Menz, Cezmi Akdis.   

Abstract

BACKGROUND: IL-32 is a proinflammatory cytokine involved in various chronic inflammatory diseases. Chronic airway inflammation in asthmatic patients results in structural airway changes, including angiogenesis. Vascular endothelial growth factor (VEGF) is a key inducer of angiogenesis in the airways of asthmatic patients.
OBJECTIVE: The aim of the study was to investigate the expression and function of IL-32 in patients with angiogenesis and asthma.
METHODS: The expression and regulation of IL-32 in normal human bronchial epithelial (NHBE) cells was analyzed by using RT-PCR, ELISA, Western blotting, immunofluorescent staining, and flow cytometry. After knockdown of IL-32 in NHBE cells by small interfering RNA (siRNA) transfections, VEGF secretion was quantified by means of ELISA. New blood vessel formation was determined with human umbilical vein endothelial cells by culturing with supernatants from IL-32 siRNA-transfected NHBE cells. IL-32 was determined in serum and induced sputum samples of asthmatic patients and healthy control subjects by means of ELISA.
RESULTS: IL-32 is expressed in NHBE cells on stimulation with IFN-γ, TNF-α, T(H)1 cells, and rhinovirus. Inhibition of IL-32 expression resulted in significantly increased secretion of the proangiogenic factors VEGF and platelet-derived growth factor by NHBE cells. Human umbilical vein endothelial cells cultured in supernatants from IL-32 siRNA-transfected NHBE cells showed enhanced in vitro angiogenesis. IL-32 is detectable in induced sputum from asthmatic patients. IL-32 serum levels were significantly higher in asthmatic patients compared with those seen in healthy control subjects and correlated with response to asthma treatment.
CONCLUSION: IL-32 is induced by IFN-γ, TNF-α, T(H)1 cells, and rhinovirus in bronchial epithelial cells. It inhibits angiogenesis, and its serum levels are associated with a good treatment response in asthmatic patients.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336080     DOI: 10.1016/j.jaci.2011.12.1002

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

1.  c-Jun N-terminal kinase and Akt signalling pathways regulating tumour necrosis factor-α-induced interleukin-32 expression in human lung fibroblasts: implications in airway inflammation.

Authors:  Dagen Li; Dapeng Chen; Xuemei Zhang; Hong Wang; Zixin Song; Wenchun Xu; Yujuan He; Yibing Yin; Ju Cao
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

3.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 4.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

5.  Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Cezmi A Akdis; Claus Bachert; Cemal Cingi; Mark S Dykewicz; Peter W Hellings; Robert M Naclerio; Robert P Schleimer; Dennis Ledford
Journal:  J Allergy Clin Immunol       Date:  2013-04-12       Impact factor: 10.793

Review 6.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

Review 7.  Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways.

Authors:  Norbert Meyer; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 8.  Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β.

Authors:  O Palomares; M Martín-Fontecha; R Lauener; C Traidl-Hoffmann; O Cavkaytar; M Akdis; C A Akdis
Journal:  Genes Immun       Date:  2014-07-24       Impact factor: 2.676

9.  Increased plasma interleukin-32 expression in patients with neuromyelitis optica.

Authors:  Honghao Wang; Kai Wang; Conghui Wang; Fangcheng Xu; Wei Qiu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-11-21       Impact factor: 8.317

10.  DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis.

Authors:  Bonnie R Joubert; Janine F Felix; Paul Yousefi; Kelly M Bakulski; Allan C Just; Carrie Breton; Sarah E Reese; Christina A Markunas; Rebecca C Richmond; Cheng-Jian Xu; Leanne K Küpers; Sam S Oh; Cathrine Hoyo; Olena Gruzieva; Cilla Söderhäll; Lucas A Salas; Nour Baïz; Hongmei Zhang; Johanna Lepeule; Carlos Ruiz; Symen Ligthart; Tianyuan Wang; Jack A Taylor; Liesbeth Duijts; Gemma C Sharp; Soesma A Jankipersadsing; Roy M Nilsen; Ahmad Vaez; M Daniele Fallin; Donglei Hu; Augusto A Litonjua; Bernard F Fuemmeler; Karen Huen; Juha Kere; Inger Kull; Monica Cheng Munthe-Kaas; Ulrike Gehring; Mariona Bustamante; Marie José Saurel-Coubizolles; Bilal M Quraishi; Jie Ren; Jörg Tost; Juan R Gonzalez; Marjolein J Peters; Siri E Håberg; Zongli Xu; Joyce B van Meurs; Tom R Gaunt; Marjan Kerkhof; Eva Corpeleijn; Andrew P Feinberg; Celeste Eng; Andrea A Baccarelli; Sara E Benjamin Neelon; Asa Bradman; Simon Kebede Merid; Anna Bergström; Zdenko Herceg; Hector Hernandez-Vargas; Bert Brunekreef; Mariona Pinart; Barbara Heude; Susan Ewart; Jin Yao; Nathanaël Lemonnier; Oscar H Franco; Michael C Wu; Albert Hofman; Wendy McArdle; Pieter Van der Vlies; Fahimeh Falahi; Matthew W Gillman; Lisa F Barcellos; Ashish Kumar; Magnus Wickman; Stefano Guerra; Marie-Aline Charles; John Holloway; Charles Auffray; Henning W Tiemeier; George Davey Smith; Dirkje Postma; Marie-France Hivert; Brenda Eskenazi; Martine Vrijheid; Hasan Arshad; Josep M Antó; Abbas Dehghan; Wilfried Karmaus; Isabella Annesi-Maesano; Jordi Sunyer; Akram Ghantous; Göran Pershagen; Nina Holland; Susan K Murphy; Dawn L DeMeo; Esteban G Burchard; Christine Ladd-Acosta; Harold Snieder; Wenche Nystad; Gerard H Koppelman; Caroline L Relton; Vincent W V Jaddoe; Allen Wilcox; Erik Melén; Stephanie J London
Journal:  Am J Hum Genet       Date:  2016-03-31       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.